PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
o a collection of information unless the particles and the control of the control o Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

25 5 5 3000 E.

FATTA TRADENIEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Compl te if Known				
Application Number	10/626,389			
Filing Date	07/24/2003			
First Named Inventor	Hayashi, T. et al			
Art Unit	1615			
Examiner Name	/Humera Sheikh/			
Attorney Docket Number	1/1379			

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
HS		^{US-} 6,403,790	06/11/2002	Dach, Rolf	
HS		US- 5,942,503	08/24/1999	Jung, B. et al	
HS		^{US-} 2003/0104017	06/05/2003	Wada, K. et al	
HS		^{US-} 2003/0050303	03/13/2003	Trach, V. et al	
HS		^{US-} 2002/0094345	07/18/2002	Abelaira, S. et al	
		US-		,	
		US-			
		US-		***************************************	
		US-			
		US-			
		US-			
		US	<u> </u>		
		US-	-		

Examiner Initials*	Cite No.1		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г	
mudis	140.	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	replication of orea occurrent	Or Relevant Figures Appear	T
	ļ					F
	ļ. <u> </u>					┝
	<u> </u>					H

Examiner		Date	10/01/2006
Signature	/Humera Sheikh/	Considered	10/01/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Ber the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known Application Number 10/626,389 Filing Date 07/24/2003 First Named Inventor Hayashi, T. et al Art Unit 1615 **Examiner Name** Humera Sheikh/ 171379 Attorney Docket Number

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	<u> </u>	Number-Kind Code ² (# known)			Figures Appear		
	1	US-					
		US-					
		US-					
		US-					
	 	US-	 				
		US-	 		·		
		US-					
		US-					
		US-					
	· · · · ·	US-	1 1				
		US-					
		US-					
		US-					
		US-					
		US-					
 -		US-					
		US-					
···		US-					
	1	us-					

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.*	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	⊤ ⁴	
HS		WO 02/28373	04/11/2002	Boehringer Ingelheim			
				International GmbH			
HS		WO 02/20018	03/14/2002	Boehringer Ingelheim			
				International GmbH			
HS		WO 01/51038	07/19/2001	Laboratorios Phoenix			

Examiner Signature	/Humera Sheikh/	Date Considered	10/01/2006

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.nov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbolis as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Transation is a acacieo.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number. Complet If Kn wn			
_ Substitution to the trace to				Application Numb r	10/626,389		
INFO	DRMATION	DIS	CLOSURE	Filing Date	07/24/2003		
STATEMENT BY APPLICANT			PPLICANT	First Nam d Inventor	Hayashi, T. et al		
	diag as many she		ananan d	Art Unit	1615		
(Use as many sheets as necessary)			ecessary)	Examiner Name	/Humera Sheikh/		
Sheet	2	of	2	Attorney Docket Number	1/1379		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
HS		New antitussive medicinal compositions-comprises ketotifen, epinastine and methyl-ephedrine, methoxy-phenamine; tri:meto-quinol, theophylline, aminophylline, di:prophylline and/or proxy-phylline, Derwent Abstract XP 002225255 of JP 11071281	
HS		Internal Medicine for rhinitis-comprises phenyl-propanol-amine-, phenyl-ephedrine, methyl-ephedrine or methoxy-phenamine and ketotife fumarate and/or epinastine hydrochloride, Derwent Abstract XP 002225257 of JP10045576	
HS		Pharmaceutical Composition for common cold having improved after-taste-contains Stevia and e.g. codeine phosphate, lysozyme chloride, clemastine fumarate and ibudilast, Derwent Abstract XP002225256 of JP9052849	
HS		Patent Abstracts of Japan vol. 2003, no. 07, July 3, 2002 and JP 2003 089638 A (Taisho Pharmaceutical Co. Ltd), March 28, 2003 abstract	
		·	

Examiner		Date	40/05/000
	/Humera Sheikh/	Considered	10/01/2006
Signature	/ ···············	Constacted	· · ·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.